Ketan Mathavan

1 ta ish

Fate Therapeutics (United States)

1. FT555: Off-the-Shelf CAR-NK Cell Therapy Co-Targeting GPRC5D and CD38 for the Treatment of Multiple Myeloma

   John Reiser, Szeman Ruby Chan, Ketan Mathavan +16

   Maqola20222 iqtibos

   ABIABI:AkademIndex/2026.other.296918